Etofylline

This classification denotes a phosphodiesterase inhibitor with the molecular formula C9H12N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L164909TBI, chemically known as 3,7-dihydro-7-(2-hydroxyethyl)-1,3-dimethyl-1h-purine-2,6-dione (9ci) but generally known as etofylline, which bears US NIH Compound Identifier 1892. European Medicines Agency schedules Etofylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07324MIG. The term ETOFYLLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). ETOFYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule etofylline under HS 29395900 and SITC 54145. As of Q4 2014, ETOFYLLINE remains the US FDA Preferred Term for this commodity. Etofylline bears US NLM identifiers UMLS ID C0059871 and NCI Concept Code C80611. SMILES: O=C1N(C(=O)N(C2NCN(C12)CCO)C)C.